Postmarketing Analysis of Eosinophilic Adverse Reactions in the use of Biologic Therapies for Type 2 Inflammatory Conditions
American Journal of Rhinology & Allergy · 2025
DOI: 10.1177/19458924241280757 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Rhinology & Allergy, 2025. Verfasst von Dafna Gershnabel Milk und 2 weiteren Autor:innen. Beteiligte Einrichtung: Divisions of Rhinology, Endoscopic Skull Base Surgery, and Allergy, Department of Otolaryngology - Head Neck Surgery, Eastern Virginia Medical School…. Hauptthemen laut MEDLINE: Sinusitis, Antibodies, Monoclonal, Humanized, Eosinophilia, Nasal Polyps. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 52 Literaturangaben.
Abstract (Originalsprache)
Background
Temporary eosinophilia is a potential adverse reaction of monoclonal antibody therapies in the treatment of a variety of type 2 inflammatory conditions, including asthma and chronic rhinosinusitis with nasal polyposis (CRSwNP). The pathophysiology, epidemiology, and clinical significance of eosinophilia and eosinophilic adverse reactions following the initiation of biologic therapy are unclear.
Objectives
To describe the postmarketing, eosinophilic adverse reactions with clinical significance in patients treated with the 3 biologic therapies approved by the U.S. Food and Drug Administration (FDA) for CRSwNP: dupilumab, omalizumab, and mepolizumab.
Methods
The FDA Adverse Event Reporting System (FAERS) Public Dashboard was searched for eosinophilic adverse reactions related to dupilumab, omalizumab, and mepolizumab treatments from November 2004 to December 2022. Data regarding each of the eosinophilic adverse reactions were extracted and analyzed.
Results
A total of 218, 270, and 134 reports of eosinophilic adverse reactions were reported among patients who were treated with dupilumab, omalizumab, and mepolizumab, respectively. The most common eosinophilic adverse reaction was eosinophilic granulomatosis with polyangiitis (338 patients), followed by eosinophilic respiratory tract reactions (158 patients). The most common indication for biological treatment among the reaction groups was asthma.
Conclusions
Eosinophilic adverse reactions are rare but consequential complications of biological treatment. They are more common among patients treated for asthma and chronic rhinosinusitis with nasal polyposis. Measuring and monitoring blood eosinophil levels may be appropriate in specific clinical instances when patients are started on different biologic therapies for type 2 inflammatory conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Divisions of Rhinology, Endoscopic Skull Base Surgery, and Allergy, Department of Otolaryngology - Head Neck Surgery, Eastern Virginia Medical School, Norfolk, VA, USA.
- Division of Rhinology, Department of Otolaryngology - Head Neck Surgery, Meir Medical Center, Kfar Saba, Israel.
ORCID-Profile: Dafna Gershnabel Milk
Zitieren
APA
Gershnabel Milk, D., Lam, K. K., & Han, J. K. (2025). Postmarketing Analysis of Eosinophilic Adverse Reactions in the use of Biologic Therapies for Type 2 Inflammatory Conditions. American Journal of Rhinology & Allergy. https://doi.org/10.1177/19458924241280757
Vancouver
Gershnabel Milk D, Lam KK, Han JK. Postmarketing Analysis of Eosinophilic Adverse Reactions in the use of Biologic Therapies for Type 2 Inflammatory Conditions. American Journal of Rhinology & Allergy. 2025. doi:10.1177/19458924241280757
BibTeX
@article{GershnabelMilk2025,
author = {Gershnabel Milk, Dafna and Lam, Kent K and Han, Joseph K},
title = {Postmarketing Analysis of Eosinophilic Adverse Reactions in the use of Biologic Therapies for Type 2 Inflammatory Conditions},
journal = {American Journal of Rhinology & Allergy},
year = {2025},
doi = {10.1177/19458924241280757}
}
EUVIMED